PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar jimscottage11 (< 20) Submitted: 12/22/2011 10:01:43 AM : Outperform Start Price: $5.99 PDLI Score: +2.36

High quarterly dividend.(10% yearly) Patents expire in 2015 though.

Report this Post Reply

Featured Broker Partners


Advertisement